Regulatory Approval - GSK's blood cancer drug approval is in doubt after failing to secure backing from a US regulatory panel [1] Pharmaceutical Industry - The outcome potentially impacts GSK's market position in the blood cancer drug sector [1]

jump there. Now, we've got more news on Astroenica. We were talking about this a few days ago.Angelica Peeles has the details for us. Hi, Angelica. Hey there.That's right. So, Bloomberg is reporting that Astroenica is in talks with Summit Therapeutics to license the company's experimental lung cancer drug for up to $15 billion. Now, Bloomberg is attributing this to people familiar with the matter.Now, this has been an incredibly hot area of development. Summit has really um shephered this whole field. this ...

AstraZeneca is discussing a partnership deal with Summit Therapeutics in which it could pay as much as $15 billion over time to license a lung-cancer drug https://t.co/QRsUkHJHsQ ...